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Serious complications after carbamazepine poisoning, such as coma, seizures, respiratory failure, cardiac 
conduction abnormalities, and death are more likely with serum levels greater than 170 µmol L-1. We report 
a case of a single massive carbamazepine overdose in a 19-year-old male, following attempted suicide, 
without prior history of seizure disorder. On admission, three hours after ingestion, serum carbamazepine 
concentration was 179 µmol L-1 and Glasgow Coma Scale scored 6. The patient was intubated and 
treated with multiple doses of activated charcoal for 48 hours. Twelve hours after ingestion, two repeated 
generalised myoclonic seizures were noted when serum carbamazepine levels peaked at 181 µmol L-1, and 
were successfully treated with diazepam. Carbamazepine serum level fell within the therapeutic range 63 
hours after ingestion and the patient was discharged without any long-term sequelae. As there is no antidote 
for carbamazepine poisoning, supportive treatment remains the only, but usually potent option.
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Carbamazepine is a well known and widely used 
iminostilbene derivative anticonvulsant with a chemical 
structure closely related to cyclic antidepressants. It 
is used to control generalized and partial seizure 
disorders, bipolar and depressive disorders as well 
as migraine and chronic pain states. Due to growing 
carbamazepine indications and far greater availability 
of this drug observed over the recent years, a higher 
number of acute intoxications is to be expected (1, 
2).
Signs of toxicity usually appear at plasma 
concentrations above the upper therapeutic limit (17 
µmol L-1 to 51 µmol L-1), but serious complications, 
such as coma, seizures, respiratory failure, cardiac 
conduction abnormalities, and death are more likely 
with serum levels greater than 170 µmol L-1(3, 4). 
The highest known carbamazepine plasma levels 
associated with a fatal course were 347 µmol L-1 and 
1100 µmol L-1 (5, 6), and other previously reported 
fatalities had levels around or above 200 µmol L-1 
(3, 7-9).
Carbamazepine has a greater affinity for binding 
to the inactivated state of the sodium channel as 
opposed to the activated state, and this binding 
has the effect of increasing the number of sodium 
channels in the inactivated state. It is also a powerful 
inhibitor of the muscarinic and nicotinic acetylcholine 
receptors, N-methyl-D-aspartate (NMDA) receptors, 
and the central nervous system adenosine receptors 
(10-13).
Today, there are contraindicating reports about 
the efficiency of hemodialysis, haemoperfusion, 
plasmapheresis and multiple doses of activated 
charcoal for the treatment of carbamazepine 
poisoning (14-21). Carbamazepine overdose has 
raised controversies about the relationship between 
serum carbamazepine and the severity of toxicity and 
between the history of seizure disorder and increased 
risk of seizure (3, 4).
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We report a successful and rapid treatment outcome 
of a patient with a severe acute carbamazepine 
poisoning (peak serum concentration was 181 µmol 
L-1) due to a suicide attempt, followed by generalized 
seizures, who was treated with multiple doses of 
activated charcoal.
CASE REPORT
A 19-year-old male was found by his brother 
unconscious on the floor of his apartment and 
vomiting. He was admitted to the Emergency Unit of 
Clinical Hospital Split about 3 hours after the ingestion 
of about l0 g of carbamazepine (Tegretol, Pliva d.d., 
Croatia, 50 tablets of 200 mg), according to his elder 
brother. No history of seizure disorder was established 
from the interview with the patient’s mother, and the 
patient was not taking any medication at the time. 
The carbamazepine tablets were of his father’s. On 
admission, the patient was in stupor, scored 6 on the 
Glasgow Coma Scale, with horizontal nystagmus, 
pulse 95 bpm, and arterial blood pressure 173/107 
hPa (130/80 mm Hg). A 12-lead electrocardiogram 
revealed sinus tachycardia, PR interval 200 ms, QRS 
120 ms, and incomplete right bundle branch block. 
Body temperature reached 40 °C without signs of 
infection.
Serum carbamazepine concentration measured 
(Abbott Axsym System, Abbott Laboratories, USA) on 
admission was 179 µmol L-1 (therapeutic 17 µmol L-1 
to 51 µmol L-1) 3 hours after ingestion. Urine qualitative 
screening for drugs of abuse (benzodiazepines, opiates, 
methadone, amphetamines, cocaine, barbiturates, 
phencyclidine and cannabinoids) was positive for 
cannabinoids alone. No alcohol was detected.
Initial arterial blood gas was within the normal 
range, and there was need for mechanical ventilation. 
The patient was intubated, and a gastric lavage was 
performed, followed by initial administration of 50 g 
activated charcoal (diluted in water) via a nasogastric 
tube, with a single dose of sorbitol in addition. The 
patient was admitted to the Intensive Care Unit and 
his electrocardiogram was monitored continuously to 
detect any cardiac arrhythmias or conduction defects. 
He was detoxified with multiple doses of activated 
charcoal (50 g every 4 h for 48 h), adequately hydrated 
[2500 mL 5 % glucosaline (5 % glucose + 0.9 % NaCl, 
HZTM) i.v. per 24 h], and haemodynamic monitoring 
was also performed. Chest X-ray did not reveal 
any pathological findings. Hypokalemia (the mean 
recorded potassium concentration was 3.3 mmol L-1) 
was corrected with 7.4 % potassium chloride (Kalij-
klorid, Pliva d.d., Croatia) given intravenously. At 12 h 
after ingestion, the patient (without a previous history 
of seizure disorder) experienced two repeated, four-
minute, generalised myoclonic seizures when serum 
carbamazepine levels peaked at 181 µmol L-1. He was 
successfully treated with intravenous diazepam 10 mg 
(Normabel, Belupo, Croatia). Systolic pressure fell to 
100 hPa (75 mm Hg) after the diazepam infusion, 
and dopamine treatment started in the dose of 2 
µg kg-1 min-1. Thirty minutes later, dopamine was 
discontinued and blood pressure was 173/107 hPa 
(130/80 mm Hg). A nephrologist was consulted and he 
recommended charcoal haemoperfusion, but as the 
charcoal haemoperfusion cartridge was unavailable 
for six hours, the detoxification was continued using 
activated charcoal. The patient’s neurological status 
improved during that time, as carbamazepine serum 
levels declined (152 µmol L-1). We decided not to treat 
the patient by charcoal haemoperfusion, and multiple 
doses of activated charcoal were continued. The patient 
became responsive, opened his eyes spontaneously, 
and was oriented in space. Mean daily diuresis was 
2800 mL. On day three from the ingestion, when the 
carbamazepine level declined to 30 mmol L-1, the 
patient’s neurological status improved completely, and 
his serum potassium and body temperature reached 
normal values. A psychiatrist was also consulted, 
who diagnosed a personality disorder with external 
frustration situation. The patient was discharged and 
referred to a psychiatrist for further therapy 63 h after 
ingestion, without any long-term sequelae. A summary 
of serum carbamazepine concentrations, patient’s 
clinical course and treatment are shown in Figure 1.
Figure 1 Serum carbamazepine concentrations following the ingestion 
of 10 g of carbamazepine. MDAC stands for “multiple-dose 
activated charcoal”.
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DISCUSSION
In the reported case of poisoning with 10 g of 
immediate-release carbamazepine following attempted 
suicide, serum carbamazepine levels peaked at 181 
µmol L-1 12 h after ingestion and were associated with 
generalized myoclonic seizures. Serum concentrations 
of carbamazepine fell within the therapeutic range 
after treatment by multiple doses of activated charcoal 
for 48 h, and the patient was discharged 63 h after 
ingestion, without any long-term sequelae.
The absorption of carbamazepine from the 
gastrointestinal tract is slow and erratic, but complete. 
Peak plasma concentrations occur approximately 8 
h to12 h after ingestion, but they may be delayed 
up to 70 h after overdose. The distribution volume 
varies from 0.5 L kg-1 to 2.0 L kg-1, with 75 % plasma 
protein binding, and the plasma half-life from 18 h 
to 55 h following a single dose, and from 12 h to 
17 h in chronic therapy (2, 22). Carbamazepine is 
extensively metabolised by the liver, and the primary 
metabolite produced in the cascade of metabolites 
is carbamazepine-10, 11-epoxide, which has lower 
protein binding and a shorter half-life (5 h to10 h) than 
the parent compound (23). Carbamazepine induces 
its own metabolism, and after oral administration, 
72 % of the dose is excreted in the urine and 28 % is 
eliminated in the faeces. In the urine, about 2 % of 
the dose is recovered unchanged and about 1 % as 
the pharmacologically active carbamazepine-10, 11-
epoxide metabolite (2, 22, 23).
The side effects, symptoms and the treatment 
of carbamazepine overdose have been studied 
extensively (1-22). The pathological signs seen in 
this case include neurological signs such as seizure, 
nystagmus and stupor, cardiovascular signs such as 
sinus tachycardia, incomplete right bundle branch 
block, and hypotension, and other findings such as 
hyperthermia, vomiting, and hypokalaemia. Seizures 
are not uncommon, occurring in 11 % to 18 % of 
overdose patients, but are usually discrete (3-5, 24). 
A peak carbamazepine concentration above 170 µmol 
L-1 is associated with a significantly greater degree of 
hypokalemia, suggesting a dose-related effect; in our 
case probably caused by vomiting (24).
The management of carbamazepine poisoning 
is primarily supportive, and although other authors 
suggest that haemoperfusion is a better option 
than haemodialysis, this has been challenged 
(15-17). Schuerer et al. reported high-efficiency 
hemodialysis clearance rates similar or better than 
those attributed to haemoperfusion (16). Finally, its 
advantage over hemodialysis is that it has no side 
effects associated with haemoperfusion such as 
hypocalcaemia, thrombocytopoenia, coagulopathies, 
and hypothermia. Furthermore, Duzova et al. 
suggested that a simple plasma exchange by 
plasma replacement is an effective method to treat 
carbamazepine poisoning (18).
Act ivated charcoal  is  known to bind to 
carbamazepine, and is recommended by the 
American Academy of Clinical Toxicologists and the 
European Association of Poison Centres and Clinical 
Toxicologists for the management of severe or life-
threatening carbamazepine poisoning. The use of 
multiple doses of activated charcoal has been shown 
to increase clearance and reduce the half-life of the 
drug (20, 21). However, it should be noted that, 
at this point, there are no prospective controlled 
studies to demonstrate an improved clinical outcome 
following the use of multidose activated charcoal in 
carbamazepine poisoning. Present recommendations 
discourage routine use of forced diuresis in the 
treatment of carbamazepine poisoning, because 
tubular resorption renders forced diuresis ineffective. 
It does not enhance carbamazepine elimination and 
can even increase the risk of electrolyte disturbances. 
Fluids and vasopressors should be given for 
haemodynamic instability as required (24).
Carbamazepine powerfully inhibits gastrointestinal 
motility (clinicians should be careful to monitor the 
patient for the development of intestinal ileus), and 
this was reason for us to perform gastric lavage, even 
though three hours had passed after drug ingestion, 
which is contrary to conventional international 
guidelines (26).
We report a successful treatment of life-threatening 
carbamazepine poisoning by multidose activated 
charcoal during 48 h, without the development of 
ileus. Although hemopurfusion was indicated when 
generalized myoclonic seizures appeared and serum 
carbamazepine levels peaked at 181 µmol L-1, but 
as the charcoal haemoperfusion cartridge was 
unavailable for 6 h, the detoxification was continued 
using activated charcoal, and the patient’s neurological 
status improved with the decline in carbamazepine 
serum levels. Although Wason et al. reported that 
multidose activated charcoal was not associated 
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with a more rapid clinical recovery, our experience is 
the opposite. We did not note any development of 
urinary retention, which is possible antidiuretic effect 
of carbamazepine.
According to Hojer et al. serious complications, 
such as coma, seizures, respiratory depression 
and cardiac conduction abnormalities, in our case 
seizures, are more likely with serum levels greater 
than 170 µmol L-1 (3). This correlation between serum 
carbamazepine and toxicity was confirmed in our case 
with seizures. Although Spiller et al. and Weaver et al. 
reported that a history of a seizure disorder appears 
to pose increased risk of seizure in carbamazepine 
overdose, generalized myoclonic seizures in our case 
were without a prior history of seizure disorder (4, 25). 
In addition, Hojer et al. have not found a significant 
correlation between the occurrence of seizures and 
the history of epilepsy (3).
Our case of acute carbamazepine poisoning 
is remarkable because of the fast and favourable 
outcome of the treatment with multidose activated 
charcoal in spite of high carbamazepine serum 
levels of up to 181 µmol L-1. Also remarkable is 
the successful diazepam treatment of generalized 
seizures without prior history of epileptic disorder. In 
this situation, potential enzyme saturation and auto-
induction could render the interpretation of plasma 
concentrations extremely difficult.
Although there is no antidote for carbamazepine 
poisoning, supportive treatment remains the only, but 
usually potent option.
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Sažetak
OPIS VIŠEKRATNE PRIMJENE AKTIVNOG UGLJENA U LIJEÈENJU PREDOZIRANJA 
KARBAMAZEPINOM POPRAÆENOG EPILEPTIÈKIM NAPADAJIMA
Pri razinama u serumu višim od 170 µmol L-1 veæi su izgledi da æe trovanje karbamazepinom dovesti 
do ozbiljnih komplikacija poput kome, epileptièkih napadaja, zatajenja dišnog sustava, poremeæaja u 
srèanoj provodljivosti te smrti. U ovome je opažanju prikazan sluèaj jednokratnoga snažnog predoziranja 
karbamazepinom prilikom pokušaja samoubojstva devetnaestogodišnjaka bez povijesti epileptièkih 
napadaja. Koncentracija karbamazepina u trenutku prijma, a tri sata nakon unosa, bila je 179 µmol L-1, 
a ocjena kome prema Glasgowskoj ljestvici (engl. Glasgow Coma Scale) bila je 6. Bolesnik je intubiran 
endotrahealno i lijeèen 48 sati višekratnim dozama aktivnog ugljena. Dvanaest sati nakon uzimanja otrova 
zabilježena su dva mioklonièka napadaja pri vršnim koncentracijama karbamazepina od 181 µmol L-1 koji 
su uspješno lijeèeni diazepamom. Razine karbamazepina u serumu spustile su se na terapijsku razinu 63 
sata nakon unosa te je bolesnik otpušten iz bolnice bez dugotrajnih posljedica. Buduæi da nema protuotrova 
za karbamazepin, potporno je lijeèenje i dalje jedini, ali djelotvoran izbor.
KLJUÈNE RIJEÈI: mioklonièki napadaj, samoubojstvo, trovanje
REQUESTS FOR REPRINTS:
Ivana Jukiæ, M.D.
Department of Internal Medicine, Clinical Hospital Split
Spinèiæeva 1, HR-21000 Split, Croatia
E-mail: ivjukic@yahoo.com
Miše S, et al. TREATMENT OF CARBAMAZEPINE OVERDOSE WITH SEIZURES
Arh Hig Rada Toksikol 2005;56:333-338
